Nanoform Finland Oyj
0.70
EUR
-0.03
(-4.11%)
ISIN
FI4000330972
Return %
Stock
S&P 500
1Y
-40.17
14.20
3Y
-55.70
81.12
5Y
-90.79
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Quarterly Revenue
EUR
•
in mil. unless spec.Quarterly Earnings Per Share
EUR
•
in mil. unless spec.Quarterly Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Edward Hæggström
- Full Time Employees
- 171
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Cultivator II Helsinki UU Finland 00790
- IPO Date
- Jun 4, 2020
- Website
- nanoform.com
- Similar Companies
- Business
- Nanoform Finland Oyj Nanoform Finland Oyj provides expert nanotechnology and drug particle engineering services to the global pharmaceutical and biotechnology industries, specializing in nanoforming technologies that enhance drug solubility, bioavailability, and delivery profiles. The company offers Controlled Expansion of Supercritical Solutions (CESS) technology for producing active pharmaceutical ingredient (API) nanoparticles as small as 10 nm directly from solution; biological nanoforming for proteins, peptides, and biologics enabling higher drug loading, long-acting delivery, and alternative administration routes such as subcutaneous injectables and inhaled forms; formulation services for optimized tablet regimens and flexible dosage forms; GMP manufacturing for clinical- and commercial-scale supply including high-potency handling; analytical capabilities for material characterization; and the STARMAP online AI platform for selecting optimal candidate molecules for nanoforming. Nanoform operates primarily in Europe and the United States through its Finnish production, research, and development facilities and subsidiary Nanoform USA Inc., targeting pharma and biotech partners to reduce clinical attrition and enable novel drug applications across small- and large-molecule therapeutics. Founded in 2015 and headquartered at Viikinkaari 4 in Helsinki, Finland, the company recently established BRAFMed Lda in October 2025 with partners A.forall and IMGA Futurum Tech Fund to advance clinical development and outlicensing of Nanoencorafenib, a patient-centric nanoformulation of encorafenib for melanoma and other cancers; partnered with Revio Therapeutics in October 2025 to co-develop and commercialize GLIORA, a nano-formulated hydrogel combination of olaparib and temozolomide for high-grade glioma treatment; and received a commercial cGMP manufacturing license as part of ongoing momentum in its kernel programs.